The shares of Xerox Holdings Corporation (NYSE:XRX) has been pegged with a rating of Equal-Weight by Morgan Stanley in its latest research note that was published on January 27, 2020. The Technology company has also assigned a $34 price target. Morgan Stanley wasn’t the only research firm that published a report of Xerox Holdings Corporation, with other equities research analysts also giving their opinion on the stock. JP Morgan advised investors in its research note published on November 12, 2019, to Neutral the XRX stock while also putting a $38 price target. The stock had earned Underweight rating from JP Morgan Markets when it published its report on October 30, 2019. That day the JP Morgan set price target on the stock to $31. The stock was given Outperform rating by Credit Suisse in its report released on April 11, 2019, the day when the price target on the stock was placed at 42. Citigroup was of a view that XRX is Buy in its latest report on July 20, 2018. JP Morgan thinks that XRX is worth Neutral rating.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The price of the stock the last time has raised by 40.15% from its 52-Week high price while it is -3.24% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 60.19.
The shares of the company added by 1.81% during the trading session on Wednesday, reaching a low of $37.65 while ending the day at $38.19. During the trading session, a total of 2.25 million shares were traded which represents a -9.96% decline from the average session volume which is 2.05 million shares. XRX had ended its last session trading at $37.51. Xerox Holdings Corporation currently has a market cap of $8.37 billion, while its P/E ratio stands at 11.76, while its P/E earnings growth sits at 3.56, with a beta of 1.88. Xerox Holdings Corporation debt-to-equity ratio currently stands at 1.00, while its quick ratio hovers at 0.90 XRX 52-week low price stands at $27.25 while its 52-week high price is $39.47.
The company in its last quarterly report recorded $1.33 earnings per share which is above the predicted by most analysts. The Xerox Holdings Corporation generated 922.0 million in revenue during the last quarter. In the second quarter last year, the firm recorded $1.08 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 31.58%. Xerox Holdings Corporation has the potential to record 3.68 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Citigroup published a research note on January 03, 2020 where it informed investors and clients that MEDNAX Inc. (NYSE:MD) is now rated as Neutral. Their price target on the stock stands at $29. Stifel also rated MD as Upgrade on December 12, 2019, with its price target of $33 suggesting that MD could surge by 2.75% from its current share price. Even though the stock has been trading at $26.50/share, analysts expect it to down by 0.00% to reach $27.25/share. It started the day trading at $27.00 and traded between $26.25 and $26.50 throughout the trading session.
A look at its technical shows that MD’s 50-day SMA is 26.56 while its 200-day SMA stands at 24.86. The stock has a high of $37.41 for the year while the low is $19.93. The stock, however, witnessed a rise in its short on 01/31/20. Compared to previous close which recorded 6.07 M shorted shares, the short percentage went lower by -11.11%, as 5.40M XRX shares were shorted. At the moment, only 7.48% of MEDNAX Inc. shares were sold short. The company’s average trading volume currently stands at 1.02M shares, which means that the short-interest ratio is just 5.99 days. Over the past seven days, the company moved, with its shift of 4.74%. Looking further, the stock has raised 2.71% over the past 90 days while it gained 21.45% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The The Vanguard Group, Inc. sold more MD shares, decreasing its portfolio by -4.77% during the last quarter. This move now sees The The Vanguard Group, Inc. selling -375,019 shares in the last quarter, thus it now holds 7,480,978 shares of MD, with a total valuation of $172,586,162. BlackRock Fund Advisors meanwhile sold more MD shares in the recently filed quarter, changing its stake to $161,703,351 worth of shares.
Similarly, ArrowMark Colorado Holdings LLC increased its MEDNAX Inc. shares by 48.01% during the recently filed quarter. After buying 5,289,078 shares in the last quarter, the firm now controls 1,715,636 shares of MEDNAX Inc. which are valued at $122,019,029. In the same vein, Dimensional Fund Advisors LP increased its MEDNAX Inc. shares by during the most recent reported quarter. The firm bought 454,203 shares during the quarter which increased its stakes to 4,627,455 shares and is now valued at $106,755,387. Following these latest developments, around 0.80% of MEDNAX Inc. stocks are owned by institutional investors and hedge funds.